nizatidine nizatidine nizatidine is a histamine h2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. nizatidineclinical datatrade namesaxid, tazacahfs/drugs.commonographmedlineplusa694030license data us dailymed: nizatidine us fda: nizatidine pregnancycategory au: b3 routes ofadministrationby mouthatc codea02ba04 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: otc / rx-only pharmacokinetic databioavailability>70%protein binding35%metabolismliverelimination half-life1–2 hoursexcretionkidneyidentifiers iupac name (e)-1-n'--1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine cas number76963-41-2 ypubchem cid3033637iuphar/bps7248drugbankdb00585 ychemspider2298266 yuniip41pml4ghrkeggd00440 ychebichebi:7601 nchemblchembl653 ycomptox dashboard (epa)dtxsid5023376 echa infocard100.155.683 chemical and physical dataformulac12h21n5o2s2molar mass331.45 g·mol−13d model (jsmol)interactive image smiles (=o)\c=c(/nc)nccscc1nc(sc1)cn(c)c inchi inchi=1s/c12h21n5o2s2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14h,4-5,7-8h2,1-3h3/b11-6+ ykey:sgxxnsqhwdmggp-izzdovswsa-n y ny (what is this?) (verify) it was patented in 1980 and approved for medical use in 1988. it was developed by eli lilly. brand names include tazac and axid. medical use main article: h2 antagonist nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (gerd/gord), and to prevent stress ulcers. adverse effects side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches. history and development nizatidine was developed by eli lilly, and was first marketed in 1988. it is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. in september 2000, eli lilly announced they would sell the sales and marketing rights for axid to reliant pharmaceuticals. subsequently, reliant developed the oral solution of axid, marketing this in 2004, after gaining approval from the u.s. food and drug administration (fda). however, a year later, they sold rights of the axid oral solution (including the issued patent protecting the product) to braintree laboratories. nizatidine proved to be the last new histamine h2 receptor antagonist introduced prior to the advent of proton pump inhibitors. axid (nizatidine) drug recalled due to presence of ndma.